Change of Antibiotic Susceptibility Testing Guidelines from CLSI to EUCAST: Influence on Cumulative Hospital Antibiograms

PLOS ONE, Dec 2019

Objective We studied whether the change in antibiotic susceptibility testing (AST) guidelines from CLSI to EUCAST influenced cumulative antibiograms in a tertiary care hospital in Switzerland. Methods Antibiotic susceptibilities of non-duplicate isolates collected within a one-year period before (period A) and after (period B) changing AST interpretation from CLSI 2009 to EUCAST 1.3 (2011) guidelines were analysed. In addition, period B isolates were reinterpreted according to the CLSI 2009, CLSI 2013 and EUCAST 3.1 (2013) guidelines. Results The majority of species/drug combinations showed no differences in susceptibility rates comparing periods A and B. However, in some gram-negative bacilli, decreased susceptibility rates were observed when comparing CLSI 2009 with EUCAST 1.3 within period B: Escherichia coli / cefepime, 95.8% (CLSI 2009) vs. 93.1% (EUCAST 1.3), P=0.005; Enterobacter cloacae / cefepime, 97.0 (CLSI 2009) vs. 90.5% (EUCAST 1.3), P=0.012; Pseudomonas aeruginosa / meropenem, 88.1% (CLSI 2009) vs. 78.3% (EUCAST 1.3), P=0.002. These differences were still evident when comparing susceptibility rates according to the CLSI 2013 guideline with EUCAST 3.1 guideline. For P. aeruginosa and imipenem, a trend towards a lower antibiotic susceptibility rate in ICUs compared to general wards turned into a significant difference after the change to EUCAST: 87.9% vs. 79.8%, P=0.08 (CLSI 2009) and 86.3% vs. 76.8%, P=0.048 (EUCAST 1.3). Conclusions The change of AST guidelines from CLSI to EUCAST led to a clinically relevant decrease of susceptibility rates in cumulative antibiograms for defined species/drug combinations, particularly in those with considerable differences in clinical susceptibility breakpoints between the two guidelines.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0079130&type=printable

Change of Antibiotic Susceptibility Testing Guidelines from CLSI to EUCAST: Influence on Cumulative Hospital Antibiograms

et al. (2013) Change of Antibiotic Susceptibility Testing Guidelines from CLSI to EUCAST: Influence on Cumulative Hospital Antibiograms . PLoS ONE 8(11): e79130. doi:10.1371/journal.pone.0079130 Change of Antibiotic Susceptibility Testing Guidelines from CLSI to EUCAST: Influence on Cumulative Hospital Antibiograms Aline Wolfensberger 0 1 Hugo Sax 0 1 Rainer Weber 0 1 Reinhard Zbinden 0 1 Stefan P. Kuster 0 1 Michael 0 1 Vishnu Chaturvedi, California Department of Public Health, United States of America 0 the Clinical and Laboratory Standards Institute (CLSI) 2009 1 1 Division of Infectious Diseases and Hospital Epidemiology, University Hospital and University of Zurich , Zurich , Switzerland , 2 Institute of Medical Microbiology, University of Zurich , Zurich , Switzerland Objective: We studied whether the change in antibiotic susceptibility testing (AST) guidelines from CLSI to EUCAST influenced cumulative antibiograms in a tertiary care hospital in Switzerland. Methods: Antibiotic susceptibilities of non-duplicate isolates collected within a one-year period before (period A) and after (period B) changing AST interpretation from CLSI 2009 to EUCAST 1.3 (2011) guidelines were analysed. In addition, period B isolates were reinterpreted according to the CLSI 2009, CLSI 2013 and EUCAST 3.1 (2013) guidelines. Results: The majority of species/drug combinations showed no differences in susceptibility rates comparing periods A and B. However, in some gram-negative bacilli, decreased susceptibility rates were observed when comparing CLSI 2009 with EUCAST 1.3 within period B: Escherichia coli / cefepime, 95.8% (CLSI 2009) vs. 93.1% (EUCAST 1.3), P=0.005; Enterobacter cloacae / cefepime, 97.0 (CLSI 2009) vs. 90.5% (EUCAST 1.3), P=0.012; Pseudomonas aeruginosa / meropenem, 88.1% (CLSI 2009) vs. 78.3% (EUCAST 1.3), P=0.002. These differences were still evident when comparing susceptibility rates according to the CLSI 2013 guideline with EUCAST 3.1 guideline. For P. aeruginosa and imipenem, a trend towards a lower antibiotic susceptibility rate in ICUs compared to general wards turned into a significant difference after the change to EUCAST: 87.9% vs. 79.8%, P=0.08 (CLSI 2009) and 86.3% vs. 76.8%, P=0.048 (EUCAST 1.3). Conclusions: The change of AST guidelines from CLSI to EUCAST led to a clinically relevant decrease of susceptibility rates in cumulative antibiograms for defined species/drug combinations, particularly in those with considerable differences in clinical susceptibility breakpoints between the two guidelines. - These authors contributed equally to this work. The European Committee for Antimicrobial Susceptibility Testing (EUCAST) was initiated to harmonize inhibitory concentration (MIC) breakpoints across Europe [1]. In line with many European clinical laboratories, the University of changed its antibiotic susceptibility testing (AST) system from methodology to the EUCAST 1.3 AST guidelines on 1st July In general, EUCAST recommends lower resistance MIC breakpoints than CLSI, in particular for Gram-negative bacteria, and, in part, abandoned the intermediate susceptibility zone. These changes have been shown to result in different susceptibility rates, e.g. higher cefepime and meropenem resistance rates in Pseudomonas aeruginosa [4], higher ceftazidime and ceftriaxone resistance rates in Escherichia coli causing bacteremia [5], higher ceftazidime resistance in ESBLproducing E. coli and Klebsiella pneumonia [6], and higher cefepime and ceftazidime resistance in ESBL producing E. coli [7]. However, the actual effect of the guideline changes on cumulative hospital antibiograms is unknown, even though local cumulative antibiograms are important for guiding empirical antibiotic therapy [8,9], and changes in cumulative resistance rates may influence the choice of empirical antimicrobial treatment [10]. This study was designed to determine whether and to which extent susceptibility rates in cumulative antibiograms of the five most prevalent bacterial species in our tertiary-care hospital would differ between two consecutive years before and after changing from CLSI 2009 to EUCAST 1.3 (2011) AST guidelines. Furthermore, we determined whether differences in cumulative antibiograms represented true changes in antimicrobial susceptibility, or if they were merely an effect of guideline changes. In addition, as resistance rates of cumulative antibiograms from general ward specimens reportedly differ from those found on intensive care units (ICUs), we aimed to determine whether guideline dependent changes differed between ICUs and general wards [11,12]. Materials and Methods Setting The University Hospital Zurich, Zurich, Switzerland, is an 871 bed tertiary-care teaching hospital covering all medical specialties except paediatrics and orthopaedics. Six intensive care units (medical ICU, general, thoracic and transplant surgery ICU, trauma ICU, burn ICU, cardiac surgery ICU, neurosurgery ICU) with a total of 65 (...truncated)


This is a preview of a remote PDF: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0079130&type=printable

Aline Wolfensberger, Hugo Sax, Rainer Weber, Reinhard Zbinden, Stefan P. Kuster, Michael Hombach. Change of Antibiotic Susceptibility Testing Guidelines from CLSI to EUCAST: Influence on Cumulative Hospital Antibiograms, PLOS ONE, 2013, 11, DOI: 10.1371/journal.pone.0079130